Results 1 to 10 of about 117,625 (136)

Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse [PDF]

, 2011
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
BB Dawood, BF McAdam, BJ Whittle, C Baigent, C Bombardier, C Moore, C Patrono, C Patrono, C Patrono, C Tymvios, CM Potter, D Pratico, EM Antman, F Catella-Lawson, F Giuliano, F Giuliano, G Davi, Harald H. H. W. Schmidt, JA Mitchell, Jane A. Mitchell, JJ Talley, LK Jennings, Michael Emerson, MJ Cho, N Zidar, NA Flavahan, Nicholas S. Kirkby, Paul C. Armstrong, PC Armstrong, PM Kearney, RF Storey, RJ Gryglewski, S Cronberg, S Krishnamurthi, S Moncada, SP Jackson, T Grosser, TD Warner, TD Warner, TD Warner, Timothy D. Warner, TT Niemi, WB White, Zetty N. Zain   +43 more
core   +11 more sources

Repurposing cancer drugs, batimastat and marimastat, to inhibit the activity of a group I metalloprotease from the venom of the Western Diamondback rattlesnake, Crotalus atrox [PDF]

, 2020
Snakebite envenomation causes over 140,000 deaths every year predominantly in developing countries. As a result, it is one of the most lethal neglected tropical diseases.
Bicknell, Andrew B., Lakshminarayanan, Karthik, Layfield, Harry J., Mehmi, Amita, Patel, Ketan, Ravishankar, Divyashree, Salim, Anika, Sonavane, Medha, Trim, Steven A., Vaiyapuri, Rajendran, Vaiyapuri, Sakthivel, Vallance, Thomas M., Williams, Harry F.   +12 more
core   +1 more source

Paradigm of biased PAR1 (protease-activated receptor-1) activation and inhibition in endothelial cells dissected by phosphoproteomics [PDF]

, 2017
Thrombin is the key serine protease of the coagulation cascade and mediates cellular responses by activation of PARs (protease-activated receptors). The predominant thrombin receptor is PAR1, and in endothelial cells (ECs), thrombin dynamically regulates
Hoogendijk, Arie J., Meijer, Alexander B., Mertens, Koen, Simpson, Pelle J., van Alphen, Floris P.J., van den Biggelaar, Maartje, van den Eshof, Bart L., Zanivan, Sara   +7 more
core   +7 more sources

clotFoam: An Open-Source Framework to Simulate Blood Clot Formation Under Arterial Flow [PDF]

SoftwareX (2023) 101483, 2023
Blood clotting involves the coupled processes of platelet aggregation and coagulation. Simulating clotting under flow in complex geometries is challenging due to multiple temporal and spatial scales and high computational cost. clotFoam is an open-source software developed in OpenFOAM that employs a continuum model of platelet advection, diffusion, and
arxiv   +1 more source

Mechanobiology of shear-induced platelet aggregation leading to occlusive arterial thrombosis: a multiscale in silico analysis [PDF]

, 2021
Occlusive thrombosis in arteries causes heart attacks and strokes. The rapid growth of thrombus at elevated shear rates (~10,000 1/s) relies on shear-induced platelet aggregation (SIPA) thought to come about from the entanglement of von Willebrand factor (VWF) molecules.
arxiv   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

Glycoprotein Ib activation by thrombin stimulates the energy metabolism in human platelets [PDF]

, 2017
Thrombin-induced platelet activation requires substantial amounts of ATP. However, the specific contribution of each ATP-generating pathway i.e., oxidative phosphorylation (OxPhos) versus glycolysis and the biochemical mechanisms involved in the thrombin-
A Archiche, A Ferreta, A Kasirer-Friede, A Lechi, A Marín-Hernández, AI Schafer, AJM Verhoeven, AM Amorini, AN Sveshnikova, AR Gear, Christian Schulz, D Banerjee, DA Slatter, E De Candia, E De Candia, F Adam, F Sinigaglia, G Solsau, GN Bijur, H Kilkson, HU Bergmeyer, I Fisher, I Hernández-Reséndiz, Ileana Hernández-Reséndiz, J Deprez, JRS Day, JW Akkerman, JY Jang, KS Authi, L Brass, LR Sorbara, M Baggiolini, Manuel Gutiérrez-Aguilar, MH Rider, MR Wardell, MY Shen, N Cardenes, N Corona de la Peña, NM Bressler, Norma Corona de la Peña, RA Nakashima, RL Elstrom, RM Denton, RW Moreadith, S Kim, S Offermans, S Ravi, S Rodríguez-Enríquez, S Zharikov, Sara Rodríguez-Enríquez, SI Obydennyy, T Sabo, V Vasta, Y Dobrydneva, Y Dobrydneva, ZP Shaik, Álvaro Marín-Hernández   +56 more
core   +4 more sources

Serotonin reuptake inhibitors and cardiovascular disease [PDF]

, 2005
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels.
Belcher, P.R., Drake-Holland, A.J., Noble, M.   +2 more
core   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +1 more source

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]

, 2002
BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Bertuglia, Silva, Giusti, Andrea
core   +2 more sources